Investigational Drug Details
| Drug ID: | D028 |
| Drug Name: | Belapectin |
| Synonyms: | GR-MD-02; Belapectin |
| Type: | Chemical drug |
| DrugBank ID: | DB15125 |
| DrugBank Description: | Belapectin is under investigation in clinical trial NCT02575404 (GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients). |
| PubChem ID: | -- |
| CasNo: | 1980787-47-0 |
| Repositioning for NAFLD: | No |
| SMILES: | -- |
| InChiKey: | -- |
| Molecular Weight: | -- |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | Gelactin-3 inhibitor; LGALS3 inhibitor |
| Therapeutic Category: | Anti-fibrosis |
| Clinical Trial Progress: | Phase 2 completed (In a phase 2b study of 162 patients with NASH, cirrhosis, and portal hypertension, 1 year of biweekly infusion of belapectin was safe but not associated with significant reduction in HVPG or fibrosis compared with placebo. However, in a subgroup analysis of patients without esophageal varices, 2 mg/kg belapectin did reduce HVPG and development of varices. ClinicalTrials.gov number: NCT02462967.) |
| Latest Progress: | Failed in clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0362 | NCT04365868 | Phase 2/Phase 3 | Recruiting | No Results Available | June 22, 2020 | March 7, 2022 | Details |
| L0394 | EUCTR2019-001983-31-ES | Phase 2 | Authorised | No Results Available | 17/02/2021 | 7 June 2021 | Details |
| L0400 | EUCTR2019-001983-31-PL | Phase 2 | Authorised | No Results Available | 29/12/2020 | 21 July 2021 | Details |
| L0420 | EUCTR2019-001983-31-GB | Phase 2 | Authorised | No Results Available | 05/08/2020 | 30 November 2020 | Details |
| L0422 | EUCTR2019-001983-31-FR | Phase 2 | Authorised | No Results Available | 04/08/2020 | 10 May 2021 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S03 | Anti-fibrosis | fibrosis | Angiotensin Receptor Blocker (ARB); CCR2/CCR5 antagonist; Thyroid receptor β agonist; PEGylated human FGF21 analogue; Monoclonal antibody to lysyl oxidase-like 2 (LOXL2); Galectin-3 inhibitor; FGF19 variant | Losartan; Cenicriviroc; VK-2809; MGL-3196; Pegbelfermin; Simtuzumab; GR-MD-02; NGM282 | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A01853 | 34588764 | Drug Des Devel Ther | Non-Alcoholic Steatohepatitis (NASH) - A Review of a Crowded Clinical Landscape, Driven by a Complex Disease. | Details |
| A04450 | 33612037 | Expert Rev Clin Pharmacol | Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis. | Details |
| A09265 | 31812510 | Gastroenterology | Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension. | Details |